RT Journal Article
T1 Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain.
A1 Ortuzar, Ariana
A1 Fox, María Laura
A1 Vera, Juan Antonio
A1 Lorenzo Vizcaya, Álvaro
A1 Marín Sánchez, Alberto
A1 Llopis Calatayud, Inmaculada
A1 Carbonell, Sara
A1 Álvarez-Larrán, Alberto
A1 Mata Serna, Raquel
A1 Marco Buades, Josefa E
A1 Quiroz Cervantes, Keina
A1 Martínez Hellín, Ángela
A1 Blum Domínguez, Alejandra
A1 Caballero Navarro, Gonzalo
A1 Cáceres Sansaloni, Amparo
A1 Guerrero Fernández, Lucía
A1 Muñoz Linares, Cristina
A1 Gasior Kabat, Mercedes
A1 Pérez López, Raúl
A1 Fernández Rodríguez, Ángeles
A1 Martínez Bilbao, Cristina
A1 Cobo Rodríguez, María Teresa
A1 Díaz, Álvaro
A1 Durán, M Antonia
A1 Santaliestra Tomas, Marta
A1 García-Gutierrez, Valentín
A1 Magro Mazo, Elena
A1 Hernández-Boluda, Juan Carlos
A1 Segura, Adrián
A1 Raya, José María
A1 Navas Elorza, Begoña
A1 Osorio, Santiago
K1 COVID-19
K1 Follow-up
K1 Patient satisfaction
K1 Ph-MPN
K1 Spain
K1 Telemedicine
AB The SARS-CoV-2 pandemic has favored the expansion of telemedicine. Philadelphia-negative chronic myeloproliferative neoplasms (Ph-MPN) might be good candidates for virtual follow-up. In this study, we aimed to analyze the follow-up of patients with Ph-MPN in Spain during COVID-19, its effectiveness, and acceptance among patients. We present a multicenter retrospective study from 30 centers. Five hundred forty-one patients were included with a median age of 67 years (yr). With a median follow-up of 19 months, 4410 appointments were recorded. The median of visits per patient was 7 and median periodicity was 2.7 months; significantly more visits and a higher frequency of them were registered in myelofibrosis (MF) patients. 60.1% of visits were in-person, 39.5% were by telephone, and 0.3% were videocall visits, with a predominance of telephone visits for essential thrombocythemia (ET) and polycythemia vera (PV) patients over MF, as well as for younger patients (
YR 2022
FD 2022-11-23
LK http://hdl.handle.net/10668/19742
UL http://hdl.handle.net/10668/19742
LA en
DS RISalud
RD Apr 17, 2025